Epidermal growth factor receptor mutations in lung cancer

Sreenath V. Sharma, Daphne W. Bell(Harvard University), Jeffrey Settleman(Massachusetts General Hospital), Daniel A. Haber(Harvard University)

Nature reviews. Cancer

February 23, 2007

10.1038/nrc2088

Cited by 3,137

Abstract

Related Papers

ERBB receptors and cancer: the complexity of targeted inhibitors

Nancy E. Hynes, Heidi A. Lane|Nature reviews. Cancer|2005|3.3k

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Ming‐Sound Tsao, Akira Sakurada, Jean-Claude Cutz et al.|New England Journal of Medicine|2005|1.9k

BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

BindingDB|PubMed|2025|933

Essential role for oncogenic Ras in tumour maintenance

Lynda Chin, Alice Tam, Jason H. Pomerantz et al.|Nature|1999|872

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

E Rapp, Joseph L. Pater, Andrew R. Willan et al.|Journal of Clinical Oncology|1988|700